Main > GASTROENTEROLOGY > GastroEsophageal Reflux Disorder > Treatment > Mosapride. > Mosapride Citrate > NonGeneric Mosapride Citrate > Patent > Claims > Claim 1: IntraBuccal DisIntegrating > Tablet Prodg. Method. Steps (a),(b) > & (c); Medicament Mixed Any Stage > of (a) or (b) Before Tabletting: > a) Dissolve Saccharide Soly.=40- > 250 g/100 ml Water 25C Select: > MonoSaccharide Etc.; Water-Sol. > Binder: PolyVinylPyrrolidone Etc > in Water. b) Mix Soln.: Excipient > ; Granulate; Dry & Tablet Mixt. at > Low Compression Pressure; c) > Aging Tablets. Claim 4: Saccharide > Select: Erythritol Etc. Claim 11: > Medicament: Mosapride Citrate. > Patent Assignee

Product Japan. D

PATENT NUMBER This data is not available for free
PATENT GRANT DATE July 2, 2002
PATENT TITLE Disintegrating tablet in oral cavity and production thereof

PATENT ABSTRACT Method for producing intrabuccally disintegrating tablets, which comprises the following Steps (a), (b) and (c), wherein a medicament is mixed before granulation or tabletting: (a) a step of dissolving at least one saccharide having a high solubility in water and at least one water-soluble binder in water alone or in water and an alcohol; (b) a step of mixing the solution obtained in above Step (a) with at least one excipient, granulating, drying, and tabletting the mixture under a low compression pressure; (c) a step of aging the tablets obtained in Step (b), and intrabuccally disintegrating tablets produced by the above method are provided. The method of the present invention is a simple method for producing intrabuccally disintegrating tablets in large scale without using specific facility, and by which intrabuccally disintegrating tablets showing good disintegrating property in oral cavity as well as having sufficient strength can be obtained.

PATENT INVENTORS This data is not available for free
PATENT ASSIGNEE This data is not available for free
PATENT FILE DATE July 11, 2000
PATENT CLAIMS What is claimed is:

1. A method for producing an intrabuccally disintegrating tablet, which comprises the following Steps (a), (b) and (c), wherein a medicament is mixed at any stage of steps (a) or (b) before tabletting:

(a) a step of dissolving at least one saccharide having a high solubility of about 40 g to about 250 g in 100 ml of purified water at about 25.degree. C. and being selected from the group consisting of a monosaccharide, a sugar alcohol and a disaccharide and at least one water-soluble binder which is at least one member selected from the group consisting of polyvinylpyrrolidone, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose, and water-soluble gelatin, in water alone or in water and an alcohol;

(b) a step of mixing the solution obtained in the above Step (a) with at least one excipient, granulating, drying, and tabletting the mixture under a low compression pressure;

(c) a step of aging the tablets obtained in the above Step (b).

2. A method for producing an intrabuccally disintegrating tablet, which comprises the following Steps (a), (b) and (c), wherein a medicament is mixed at any stage of steps (a) or (b) before tabletting:

(a) a step dissolving at least one saccharide having a high solubility of about 40 g to about 250 g in 100 ml of purified water at about 25.degree. C. and being selected from the group consisting of a monosaccharide, a sugar alcohol and a disaccharide and at least one water-soluble binder which is at least one member selected from the group consisting of polyvinylpyrrolidone, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose, and water-soluble gelatin, in water alone or in water and an alcohol;

(b) a step of mixing the solution obtained in the above Step (a) with at least one excipient, granulating, drying, and tabletting the mixture under a low compression pressure of about 20 to about 300 kg/cm.sup.2 ;

(c) a step of aging the tablets obtained in the above Step (b).

3. The method according to claim 2, wherein the aging procedure of Step (c) is carried out by warming the tablets obtained in Step (b) at a temperature higher than room temperature for about 1 minute to about 3 days.

4. The method according to claim 2, wherein the saccharide used in Step (a) is at least one member selected from the group consisting of erythritol, xylitol, sorbitol, glucose, and sucrose.

5. An intrabuccally disintegrating tablet which is produced by the following Steps (a), (b) and (c), wherein a medicament is mixed at any stage of steps (a) or (b) before tabletting:

(a) A step of dissolving at least one saccharide having a high solubility of about 40 g to about 250 g in 100 ml of purified water at about 25.degree. C. and being selected from the group consisting of a monosaccharide, a sugar alcohol and a disaccharide and at least one water-soluble binder which is at least one member selected from the group consisting of polyvinylpyrrolidone, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose, and water-soluble gelatin, in water alone or in water and an alcohol;

(b) a step of mixing the solution obtained in the above Step (a) with at least one excipient, granulating, drying, and tabletting the mixture under a low compression pressure;

(c) a step of aging the tablets obtained in the above Step (b).

6. The method according to claim 1, wherein the amount of the saccharide used in Step (a) is in the range of about 0.5 to about 10% by weight to the total weight of the tablet.

7. The method according to claim 6, wherein the amount of the water-soluble binder is in the range of about 0.5 to about 5% by weight to the total weight of the tablet.

8. The method according to claim 7, wherein the aging procedure of Step (c) is carried out by warming, and the temperature for said warming is a temperature lower than a softening point of the water-soluble binder used in Step (a), but higher than about 40.degree. C., and the aging period is in the range of about 1 minute to about 24 hours.

9. The method according to claim 2, wherein a medicament is mixed before granulation or tabletting in Step (b).

10. The method according to claim 2, wherein the drying procedure of Step (b) is carried out until the surface of granules becomes dry.

11. The intrabuccally disintegrating tablet according to claim 5, wherein the medicament is mosapride citrate.

12. An intrabuccally disintegrating tablet which is produced by the following Steps (a), (b) and (c), wherein a medicament is mixed at any stage of steps (a) or (b) before tabletting;

(a) a step of dissolving at least one saccharide having a high solubility of about 40 g to about 250 g in 100 ml of purified water at about 25.degree. C. and being selected from the group consisting of a monosaccharide, a sugar alcohol and a disaccharide, and at least one water-soluble binder which is at least one member selected from the group consisting of polyvinylpyrrolidone, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose, and water-soluble gelatin, in water alone or in water and an alcohol;

(b) a step of mixing the solution obtained in the above Step (a) with at least one excipient, granulating, drying, and tabletting the mixture under a low compression pressure of about 20 to about 300 kg/cm.sup.2 ;

(c) a step of aging the tablets obtained in the above Step (b).

13. An intrabuccally disintegrating tablet which is produced by the following Steps (a), (b) and (c), wherein a medicament is mixed at any stage of steps (a) or (b) before tabletting:

(a) a step of dissolving at least one saccharide having a high solubility of about 40 g to about 250 g in 100 ml of purified water at about 25.degree. C. and being selected from the group consisting of a monosaccharide, a sugar alcohol and a disaccharide, and at least one water-soluble binder which is at least one member selected from the group consisting of polyvinylpyrrolidone, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose, and water-soluble gelatin, in water alone or in water and an alcohol;

(b) a step of mixing the solution obtained in the above Step (a) with at least one excipient, granulating, drying, and tabletting the mixture under a low compression pressure of about 20 to about 300 kg/cm.sup.2 ;

(c) a step of aging the tablets obtained in the above Step (b) by warming them at a temperature higher than room temperature for about 1 minute to about 3 days.

14. The intrabuccally disintegrating tablet according to claim 5, wherein the weight of the tablet is in the range of about 150 mg to about 300 mg.

15. The intrabuccally disintegrating tablet according to claim 12, wherein the weight of the tablet is in the range of about 150 mg to about 300 mg.

16. The intrabuccally disintegrating tablet according to claim 13, wherein the weight of the tablet is in the range of about 150 mg to about 300 mg.

17. The method for producing an intrabuccally disintegrating tablet according to claim 1, wherein the medicament is mosapride citrate.

18. The method for producing an intrabuccally disintegrating tablet according to claim 2, wherein the medicament is mosapride citrate.

19. The method for producing an intrabuccally disintegrating tablet according to claim 3, wherein the medicament is mosapride citrate.

20. The method for producing an intrabuccally disintegrating tablet according to claim 4, wherein the medicament is mosapride citrate.

21. The intrabuccally disintegrating tablet according to claim 16, wherein the medicament is mosapride citrate.

22. The method for producing an intrabuccally disintegrating tablet according to claim 6, wherein the medicament is mosapride citrate.

23. The method for producing an intrabuccally disintegrating tablet according to claim 7, wherein the medicament is mosapride citrate.

24. The method for producing an intrabuccally disintegrating tablet according to claim 8, wherein the medicament is mosapride citrate.

25. The method for producing an intrabuccally disintegrating tablet according to claim 9, wherein the medicament is mosapride citrate.

26. The method for producing an intrabuccally disintegrating tablet according to claim 10, wherein the medicament is mosapride citrate.

27. The intrabuccally disintegrating tablet according to claim 12, wherein the medicament is mosapride citrate.

28. The intrabuccally disintegrating tablet according to claim 13, wherein the medicament is mosapride citrate.

29. The intrabuccally disintegrating tablet according to claim 14, wherein the medicament is mosapride citrate.

30. The intrabuccally disintegrating tablet according to claim 15, wherein the medicament is mosapride citrate.
--------------------------------------------------------------------------------

PATENT DESCRIPTION BACKGROUND OF THE INVENTION

The present invention relates to a method for production of a tablet readily disintegrating in the oral cavity (hereinafter, referred to as "intrabuccally disintegrating tablet"), and to an intrabuccally disintegrating tablet which is produced by said method.

With the increase in the population of aged people, a pharmaceutical dosage form being capable of being easily taken by persons advanced in age has been desired, but many of pharmaceutical dosage forms for oral administration are conventional forms of tablets or capsules at the present, and it is not easy for aged people to swallow these dosage forms. Besides, these conventional dosage forms are often difficult to be swallowed by children or patients having poor swallowing capability. Moreover, powders or granules have also defects, for example, they need extra attention when being unpacked, or they adhere to the oral cavity when taken, and hence, they are not satisfactory enough for aged people, children or patients having poor swallowing capability, either. In order to overcome these problems, there have been studied on some tablets being easily taken without using water and being very easy for handling.

U.S. Pat. Nos. 4,371,516 and 4,305,502 (corresponding to JP-B-62-50445) disclose a method for producing a tablet, which comprising charging a suspension of a medicament, a saccharide and a gellant into a blister package of PTP (Press Through Package), subliming the water therefrom by lyophilization, and formulating tablets in said blister package. U.S. Pat. No. 5,466,464 (corresponding to PCT publication WO 93-12769) discloses a method for producing a tablet which comprises charging a suspension of a medicament, mannitol and agar into a blister package of PTP, subliming the water therefrom by drying under reduced pressure, and formulating tablets in said blister package.

U.S. Pat. No. 5,837,285 (corresponding to Japanese Patent No. 2650493, and PCT publication WO 93-15724) discloses a rapidly soluble tablet rapidly dissolving in the oral cavity, which is produced by compressing wet granules containing mainly saccharides granulated with water, and followed by drying thereof, and U.S. Pat. No. 5,501,861 (corresponding to Japanese Patent Publication JP-A-5-271054) discloses a method for producing an intrabuccally disintegrating tablet, which comprises compression-molding a mixture containing a barely sufficient amount of water to moisten the surface of particles. These methods are generally known as "wet-tabletting method".

JP-A-8-291051 and JP-A-9-48726 disclose a method for producing an intrabuccally disintegrating tablet, which comprising compression-molding a powder containing mainly a saccharide and a water-soluble binder under a low pressure, wetting the resulting tablets by placing them under humid, and drying them (hereinafter, occasionally referred to as "humidification method").

WO 93-13758 (corresponding to Japanese Patent No. 2640570) discloses a method for producing a tablet of increased strength, which comprises the steps of compression-molding a powder containing a water-soluble meltable binder such as polyethylene glycol with a low pressure, melting said water-soluble meltable binder in the resulting tablet at a temperature higher than a melting point of said water-soluble meltable binder, followed by solidifying said water-soluble meltable binder (hereinafter, occasionally referred to as "heat-melting method").

JP-A-9-316006 discloses a rapidly dissolving and disintegrating solid preparation in the oral cavity having a fresh feeling, which is improved by containing erythritol and a small amount of a solid organic acid.

On the other hand, as specific methods, WO 95-34290 discloses a method for producing a tablet, which comprises preparing shearform matrix in sheared cotton candy amorphous, making it flowable compactible micro-particulates, followed by compacting the resultant to give tablets, and WO 95-34293 and U.S. Pat. No. 5,654,003 (corresponding to Japanese Patent Publication JP-A-8-38138) disclose tablets using the above-mentioned shearform matrix.

All of the tablets explained in the above comprises saccharides, etc. as the main excipient, and they are porous tablets being capable of rapidly disintegrating, and produced by seeking how to increase the strength of tablets maintaining a porous property thereof, but they have problems such as complicated production procedures and in terms of the cost thereof, and hence, it has been desired to develop an excellent method in total aspects for producing an intrabuccally disintegrating tablet.

For example, the tablets obtained by a method disclosed in the above U.S. Pat. No. 4,371,516 (corresponding Japanese Patent Publication JP-B-62-50445) have weak strength, and they may have problems when pushed out from PTP. Moreover, said method has complicated production procedures, and requires additional equipment, and hence, it is not advantageous in view of the cost. On the other hand, although the tablets obtained by the method disclosed in WO 93-12769 have improved strength, said method has also complicated production procedures as the method disclosed in U.S. Pat. No. 4,371,516 (corresponding Japanese Patent Publication JP-B-62-50445) does, and hence, it is not advantageous in view of the cost.

Moreover, in the wet-tabletting methods disclosed in the above, wet powders tend to adhere to a die or a punch when tabletting, and it is also necessary to use an additional device to provide a prescribed amount of wet powders to the die, and hence, those methods are not suitable for continuous tabletting. Therefore, it becomes necessary to improve a tabletting machine per se in order to overcome these problems (see, JP-A-8-19589 and JP-A-8-19590).

Further, in the above-mentioned humidification methods, they need an additional step for humidifying tablets other than the conventional steps for producing tablets. In addition, these methods are not applicable to medicaments, which are unstable to humidity or tends to deliquesce under high humidity. Furthermore, the above-mentioned heat-melting methods also have problems such as that those methods are not applicable to medicaments being unstable to heat, or being incompatible with water-soluble meltable binders.

SUMMARY OF THE INVENTION

The present inventors have intensively studied in order to overcome the problems in the conventional methods, and have found an economically excellent method for producing an excellent intrabuccally disintegrating tablet having strength sufficient to take it out from a Press Through Pack and not to cause problems for the handling, as well as being capable of rapidly disintegrating in the oral cavity, by a conventional wet granulation using a solution prepared by dissolving a saccharide having a high solubility in water and a water-soluble binder in water.

According to the present invention, a method for producing an intrabuccally disintegrating tablet which comprises the following Steps (a), (b) and (c), wherein a medicament is mixed before granulation or tabletting:

(a) a step of dissolving at least one saccharide having a high solubility in water and at least one water-soluble binder in water alone or in water and an alcohol;

(b) a step of mixing the solution obtained in the above Step (a) with at least one excipient, granulating, drying and tabletting the mixture under a low compression pressure;

(c) a step of aging the tablets obtained in the above Step (b), and an intrabuccally disintegrating tablet produced by the above method are provided.

DETAILED DESCRIPTION OF THE INVENTION

The terms used in the present specification are explained below.

In the present specification, the term "saccharide having a high solubility in water" means a saccharide having relatively such a property among the so-called saccharides, and means ones having a solubility of about 40 g to about 250 g at about 25.degree. C. in 100 ml of purified water (hereinafter, occasionally simply referred to as "solubility", and the measurement of solubility is explained hereinbelow). These saccharides (hereinafter, occasionally referred to "the saccharide used in the present invention") include, for example, a monosaccharide such as glucose, xylose [solubility: about 125 g; Merck Index, 12th ed., 10220 (1996)], a sugar alcohol such as xylitol, sorbitol, erythritol, and a disaccharide such as sucrose (white sugar), but erythritol, xylitol and sucrose are preferable. These saccharides can be used alone or in a mixture of two or more of these saccharides, and can usually be contained in an amount of about 0.1 to about 20% by weight, preferably in an amount of about 0.5 to about 10% by weight in the present tablet.

Thus, in the present specification, for example, mannitol and lactose have a low solubility as shown in Examples as disclosed below, and cannot fall in the category of the "saccharide having a high solubility in water" of the present invention, and they are regarded as saccharides outside the saccharides used in the present invention.

The water-soluble binder includes ones which can be dissolved together with the saccharides used in the present invention in water alone or in water and an alcohol (cf. ethanol), and then, can exhibit a desired binding property, for example, polyvinylpyrrolidone, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose, acacia, water-soluble gelatin, etc., and polyvinylpyrrolidone is preferable. These water-soluble binders can be used alone or in a mixture of two or more of these water-soluble binders, and can usually be contained in an amount of about 0.1 to about 20% by weight, preferably in an amount of about 0.5 to about 5% by weight in the present tablet.

Corn starch is usually used as a binder, but the dissolving rate thereof in water is low, and as a result, a tablet being prepared by using thereof shows the delay in disintegration, and hence, corn starch cannot be used as the above-mentioned water-soluble binder in the present invention.

The excipient may usually be saccharides other than saccharides used in the present invention, for example, mannitol, lactose, mannose, but the saccharides used in the present invention can also be used as an excipient.

The intrabuccally disintegrating tablets of the present invention can be applied to any medicaments which can be formulated by a conventional wet granulation or by a conventional fluidized bed granulation, for example, citrate or citrate dihydrate of mosapride disclosed in U.S. Pat. No. 4,870,074 (chemical name: (.+-.)-4-amino-5-chloro-2-ethoxy-N-[[4-(p-fluorobenzyl)-2-morpholinyl]meth yl]benzamide) (hereinafter, simply referred to as "mosapride citrate"), alacepril (Merck Index 11th ed., 192), brotizolam (Merck Index, 11th ed., 1439), hydrochloride or tannate of berberine (Merck Index, 11th ed., 1169), and loperamide hydrochloride (Merck Index, 11th ed., 5450). The medicament can be mixed before either granulation or tabletting, and it is preferably mixed before granulation or tabletting in Step (b), more preferably before granulation in Step (b). The medicament may usually be contained in an amount of about 0.01 to about 20% by weight, preferably in an amount of about 0.1 to about 10% by weight in the present tablet.

The intrabuccally disintegrating tablet of the present invention may additionally contain a sweetening agent or a flavor in order to improve a feeling when taken, if necessary. Besides, the intrabuccally disintegrating tablet of the present invention may additionally contain a lubricant or a disintegrator which are usually necessary for conventional formulation procedures.

The tabletting procedure under a low compression pressure in Step (b) is usually carried out under a pressure of about 20 to about 300 kg/cm.sup.2, preferably under a pressure of about 50 to about 200 kg/cm.sup.2.

The drying procedure in Step (b) is preferably carried out until the surface of granules becomes dry. By the above drying, preferable flowing properties of granules are obtained.

The tablets obtained in the above Step (b) are subjected to aging in Step (c).

The "aging" means a step of making a pharmaceutical property of tablets, etc. to be stationary state, by which an intrabuccally disintegrating tablets having a desired strength can be obtained. The aging is usually carried out by allowing compositions to stand at room temperature (preferably at a temperature higher than about 15.degree. C.) for several hours to about several days, or as a positive aging, by warming compositions at a temperature higher than room temperature, preferably at a temperature higher than about 30.degree. C. for about 10 seconds to several days. The positive aging is preferably carried out by warming compositions at a temperature higher than about 40.degree. C. but lower than a softening point of a water-soluble binder used in the present invention, more preferably at a temperature of from about 40.degree. C. to about 80.degree. C., for about 1 minute to about 3 days, more preferably for about 1 minute to about 24 hours. In addition, any treatments for making the tablets etc. to be stationary state other than the methods disclosed herein can also be included in the aging procedure of the present invention.

The "softening point" means a temperature, at which a solid substance starts to soften, and can easily deform, for example, the softening point of polyvinylpyrrolidone is about 150.degree. C., and that of hydroxypropylcellulose is about 130.degree. C.

The weight of the tablets produced by the present invention may not be specified, but it is usually in the range of about 50 mg to about 500 mg, preferably in the range of about 100 mg to about 400 mg, more preferably in the range of about 150 mg to about 300 mg.

The following embodiments may be exemplified as a preferable method for producing the intrabuccally disintegrating tablets of the present invention.

A method for producing an intrabuccally disintegrating tablet, comprising the following Steps (a'), (b') and (c'), wherein a medicament is mixed before granulation or tabletting.

(a'): a step of dissolving at least one saccharide selected from the group consisting of erythritol, xylitol, sorbitol, glucose and sucrose in an amount of about 0.5 to about 10% by weight, and at least one water-soluble binder selected from the group consisting of polyvinylpyrrolidone, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose and water-soluble gelatin in an amount of about 0.5 to about 5% by weight, in water alone or in water and ethanol;

(b'): a step of mixing the solution obtained in the above Step (a') with at least one excipient, granulating, drying, and compressing the mixture under a low compression pressure of about 50 to about 200 kg/cm.sup.2 ;

(c'): a step of aging the tablets obtained in the above Step (b') at a temperature lower than a softening point of the water-soluble binder used in the above (a') but higher than about 400 for about 1 minute to about 24 hours;

The method of the present invention will be illustrated in more detail below.

A saccharide used in the present invention and a water-soluble binder are dissolved in water alone, if necessary, or with adding thereto an alcohol, and an excipient is added to the solution obtained above, and further the mixture is dried after wet kneading granulation; or a saccharide used in the present invention and a water-soluble binder are dissolved in water alone, if necessary, or with adding thereto an alcohol, and the solution thus obtained is subjected to fluidized bed granulation by spraying the mixture onto a fluidized excipient, and then the granules thus obtained are dried, to give a co-dissolved mixture of the saccharide used in the present invention and the water-soluble binder. The co-dissolved mixture is in semi-solid state and can distribute uniformly in the granules, but the surface of granules is in dry state. A medicament may be added before either granulation or tabletting, but as mentioned above, a medicament is preferably added before granulation or tabletting in Step (b). Then, the granules containing said medicament or a mixture of a medicament and the granules are compressed under a low compression pressure of about 20 to about 300 kg/cm.sup.2 to give porous tablets. The porous tablets thus obtained are still not satisfactory because they can rapidly disintegrate in the oral cavity but the strength thereof is not sufficient enough. However, these tablets can be solidified by aging, for example, by allowing them to stand at room temperature for several hours to several days, or by warming them at a temperature higher than room temperature for a dozen seconds to several days, preferably at a temperature lower than a softening point of the water-soluble binder to be used but higher than about 40.degree. C. for about 1 minute to about 24 hours. The tablets solidified by allowing to stand under the conventional conditions or by a conventional positive aging as mentioned above have high strength being sufficient for the handling, as well as they can rapidly disintegrate in the oral cavity.

PATENT EXAMPLES Available on request
PATENT PHOTOCOPY Available on request

Want more information ?
Interested in the hidden information ?
Click here and do your request.


back